Experimental pill plus chemo takes aim at Hard-to-Treat brain lymphoma
NCT ID NCT07608731
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new oral drug called golcadomide combined with standard chemotherapy drugs (pemetrexed, rituximab, and dexamethasone) in 18 adults with large B-cell lymphoma that has spread to the brain or central nervous system and has either returned or is not responding to current treatment. The main goals are to check the safety of the combination and find the best dose. Participants will receive up to six 21-day cycles of treatment and be followed for about 2.5 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Golcadomide (an experimental drug taken orally) combined with pemetrexed, rituximab, and dexamethasone (standard chemotherapy drugs)
- What this could lead to
- If this works, it could point toward a new treatment option for people with CNS lymphoma that has come back or stopped responding to therapy.
- What could go wrong
- This is a very early Phase 1 trial with only 18 participants, so it is primarily testing safety and dosing—not yet proving effectiveness. The drug combination may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic, Case Comprehensive Cancer Center
Cleveland, Ohio, 44122, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can lifestyle choices after a stroke extend life and prevent a second one?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- What happens years after CAR-T therapy? a study aims to find out
- Can a single shot build a cancer army inside the body?
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Engineered immune cells take on tough lymphomas